Efficacy of Incremental Next-Generation ALK Inhibitor Treatment in Oncogene-Addicted, ALK-Positive, TP53-Mutant NSCLC

Background: The anaplastic lymphoma kinase (ALK) gene fusion rearrangement is a potent oncogene, accounting for 2–7% of lung adenocarcinomas, with higher incidence (17–20%) in non-smokers. ALK-positive tumors are sensitive to ALK tyrosine kinase inhibitors (TKIs), thus ALK-positive non-small-cell lu...

Descripción completa

Detalles Bibliográficos
Autores principales: Urbán, László, Dóczi, Róbert, Vodicska, Barbara, Kormos, Dóra, Tóth, László, Takács, István, Várkondi, Edit, Tihanyi, Dóra, Lakatos, Dóra, Dirner, Anna, Vályi-Nagy, István, Peták, István
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563786/
https://www.ncbi.nlm.nih.gov/pubmed/32872120
http://dx.doi.org/10.3390/jpm10030107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563786/
https://www.ncbi.nlm.nih.gov/pubmed/32872120
http://dx.doi.org/10.3390/jpm10030107

Ejemplares similares